These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 35072888

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
    Van Zyl-Smit RN, Kerstjens HA, Maspero JF, Kostikas K, Hosoe M, Tanase AM, D'Andrea P, Mezzi K, Brittain D, Lawrence D, Chapman KR.
    Respir Med; 2023 May; 211():107172. PubMed ID: 36906187
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
    Scosyrev E, van Zyl-Smit R, Kerstjens H, Gessner C, Kornmann O, Jain D, Aubrun E, D'Andrea P, Hosoe M, Pethe A, Brittain D.
    Respir Med; 2021 May; 180():106311. PubMed ID: 33711782
    [Abstract] [Full Text] [Related]

  • 6. Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
    Blair HA.
    Drugs; 2021 Apr; 81(6):709-719. PubMed ID: 33871819
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
    Sagara H, D'Andrea P, Tanase AM, Pethe A, Tanaka Y, Matsuo K, Hosoe M, Nakamura Y.
    J Asthma; 2023 Feb; 60(2):403-411. PubMed ID: 35348408
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma.
    Pelaia C, Crimi C, Crimi N, Ricciardi L, Scichilone N, Valenti G, Bonavita O, Andaloro S, Morini P, Rizzi A, Pelaia G.
    Expert Rev Respir Med; 2022 Feb; 16(2):183-195. PubMed ID: 34845963
    [Abstract] [Full Text] [Related]

  • 10. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
    van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, Sagara H, Tanase AM, Hosoe M, Pethe A, Lawrence D, Tillmann HC, D'Andrea P.
    J Asthma Allergy; 2023 Feb; 16():123-134. PubMed ID: 36714049
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.
    Sagara H, Barbier N, Ishii T, Yoshisue H, Nikolaev I, Hosoe M, Gon Y.
    BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33737310
    [Abstract] [Full Text] [Related]

  • 12. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
    Mangia PP, Gallo O, Ritrovato D, Pradelli L.
    Clin Drug Investig; 2021 Sep; 41(9):785-794. PubMed ID: 34333742
    [Abstract] [Full Text] [Related]

  • 13. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
    Buhl R, Nikolaev I, Tillmann HC, Vaidya S, Bartels C, Jain M, Jauernig J, Kerstjens HAM.
    Pulm Pharmacol Ther; 2021 Oct; 70():102068. PubMed ID: 34329722
    [Abstract] [Full Text] [Related]

  • 14. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
    Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct; 13():3923-3936. PubMed ID: 30584293
    [Abstract] [Full Text] [Related]

  • 15. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
    Watz H, Hohlfeld JM, Singh D, Beier J, Diamant Z, Liu J, Hua S, Abd-Elaziz K, Pinot P, Jones I, Tillmann HC.
    Respir Res; 2020 Apr 15; 21(1):87. PubMed ID: 32295593
    [Abstract] [Full Text] [Related]

  • 16. Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma: post hoc pooled analysis from PALLADIUM and IRIDIUM studies.
    Gon Y, Ishii T, Lawrence D, Nikolaev I, Wang D, Sumi K, Nakamura Y.
    J Asthma; 2022 Aug 15; 59(8):1627-1637. PubMed ID: 34346266
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S, Vaidya S, Tillmann HC, Sakita Y, Machineni S, Heudi O, Furihata K.
    BMC Pulm Med; 2021 Jan 07; 21(1):18. PubMed ID: 33413291
    [Abstract] [Full Text] [Related]

  • 18. Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.
    de Llano LP, Naval E, Mejía N, Domínguez-Ortega J.
    Expert Rev Respir Med; 2022 Jan 07; 16(1):1-15. PubMed ID: 34783265
    [Abstract] [Full Text] [Related]

  • 19. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler® Device in Patients with Asthma.
    Bartels C, Jain M, Yu J, Tillmann HC, Vaidya S.
    Eur J Drug Metab Pharmacokinet; 2021 Jul 07; 46(4):487-504. PubMed ID: 34024035
    [Abstract] [Full Text] [Related]

  • 20. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
    Chapman K, van Zyl-Smit R, Maspero J, Kerstjens HAM, Gon Y, Hosoe M, Tanase AM, Pethe A, Shu X, D'Andrea P.
    BMJ Open Respir Res; 2021 Aug 07; 8(1):. PubMed ID: 34452934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.